78
Growth Score
pts
Heat Score
11 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
Recent Milestones
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
See more interactive data and historical milestones on desktop for the best experience
244886
Therillume is a clinical-stage neuro-oncology therapeutics company that focuses on glioblastoma and Neurofibromatosis Type 1 and 2.
- Adrienne Watson: Founder and Chief Scientific OfficerPast Role: Recombinetics, VP of Research and Development
- David Nelson: FounderPast Role: Epic Sciences, Founder
About the Company
Therillume is a clinical-stage neuro-oncology therapeutics company that focuses on glioblastoma and Neurofibromatosis Type 1 and 2 (“NF1 and NF2”). The company uses its precise gene-editing platform to identify and validate and expedite high-quality candidates through clinical development. Therillume was founded in 2021 and is located in Eagan,
Minnesota.
Women Founded
